Nutriband Inc
$ 3.55
0.00%
02 Jun - close price
- Market Cap 43,153,700 USD
- Current Price $ 3.55
- High / Low $ 3.60 / 3.40
- Stock P/E N/A
- Book Value 0.55
- EPS -2.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -1.26 %
- 52 Week High 11.68
- 52 Week Low 3.21
About
Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.
Analyst Target Price
$15.00
Quarterly Earnings
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-01 | 2026-04-29 | 2025-12-16 | 2025-09-09 | 2025-05-30 | 2025-04-28 | 2024-12-03 | 2024-09-03 | 2024-05-31 | 2024-04-30 | 2023-12-12 | 2023-09-11 |
| Reported EPS | -0.0796 | -0.04 | -0.32 | -2.12 | -0.5 | -0.51 | -0.1227 | -0.1542 | -0.2072 | -0.2295 | -0.2247 | -0.1059 |
| Estimated EPS | -1.89 | -1.89 | -2.13 | -0.17 | -0.12 | -0.12 | None | None | None | None | -0.06 | -0.07 |
| Surprise | 1.8104 | 1.85 | 1.81 | -1.95 | -0.38 | -0.39 | 0 | 0 | 0 | 0 | -0.1647 | -0.0359 |
| Surprise Percentage | 95.7884% | 97.8836% | 84.9765% | -1147.0588% | -316.6667% | -325% | None% | None% | None% | None% | -274.5% | -51.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTRB
2026-05-29 18:39:16
Nutriband, Inc. stock has fallen to a new 52-week low of $3.28, reflecting significant financial challenges in the Pharmaceuticals & Biotechnology sector. The company reported a 42.03% decline in net sales and a 47.4% net profit loss, resulting in a negative return on equity of 121.64%. This performance has led to a -43.48% return over the past year, underperforming the S&P 500.
2026-05-29 08:39:16
Nutriband Inc.'s equity buyback program, which was originally announced on September 18, 2024, has now expired. The company officially ended its plan on January 31, 2026. This announcement highlights the conclusion of their share repurchase initiative.
2026-05-29 02:08:59
Nutriband, Inc. (NTRB) has hit a new 52-week low of $3.38, with its stock declining 41.25% over the past year. The microcap pharmaceutical company faces challenges including a negative return on equity, concerning operating cash flow of -$5.64 million, and rising raw material costs. These financial hurdles highlight the difficulties microcap stocks encounter in the current market.
2026-05-20 00:10:27
Nutriband's subsidiary, Active Intelligence, will be featuring its expanding line of wellness, recovery, and performance-focused consumer products at the ECRM conference in June 2026. The company intends to showcase its existing AI Tape and unveil new products such as AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to secure more retail partnerships and distribution opportunities. Nutriband Inc. specializes in transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch.
2026-05-19 08:32:53
Nutriband Inc. recently filed an amendment to its 2026 10-K report, primarily to adopt a new Executive Compensation Clawback Policy in compliance with SEC and Nasdaq rules. This policy ensures that erroneously awarded incentive-based compensation can be recovered from executives if financial statements are restated due to material noncompliance. The amendment does not modify prior financial data and confirms that no current financial restatements are reflected in the filing.
2026-05-18 20:44:55
Nutriband Inc. has filed an amendment (10-K/A) to its annual report for the year ending January 31, 2026, to include its executive compensation Clawback Policy as Exhibit 97.1. This policy, adopted on January 24, 2026, ensures compliance with NASDAQ listing standards and SEC Rule 10D-1, allowing the company to recover erroneously awarded compensation. The amendment clarifies that no other disclosures in the original 10-K report have been modified or updated.
